[ad_1]
A spokesman for the Russian Direct Investment Fund (RDIF) said a request was submitted to the European Medicines Agency (EEA) on Tuesday for permission to distribute its pandemic coronavirus vaccine in the European Union.
“This is an important step,” he added.
The first review of the documents submitted by RDIF is scheduled for February.
The EEA confirmed that a meeting had been held with the Russian vaccine customer on Tuesday to “discuss its development plan and its future commitments to the Agency.”
However, the EEA statement states that “there is currently no in-depth examination of Sputnik V.”
“The EEA will announce the start of the peer review process,” he added.
Russia registered the world’s first vaccine against the Sputnik V coronavirus, named after the first artificial ground satellite launched by the Soviet Union, in August, but has taken that step before launching large-scale clinical trials.
Its developers claim that the vaccine is 90 percent effective. Russia launched a mass vaccination campaign in the country this week.
According to RDIF, this vaccine has already been registered in a chain of countries around the world, including Belarus, Venezuela, Bolivia and Algeria.
Argentina, which began to be vaccinated with a Russian vaccine in late December, began vaccination with a second dose of Sputnik V this week.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
